Novel antibody candidate shows powerful binding to different SARS-CoV-2 variant mutations Kumar Jeetendra | September 25, 2021 Twist Bioscience Corporation today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19. The Coronavirus Immunotherapy Consortium (CoVIC) is an academic-industry-non-profit …
